NMRA (Neumora Therapeutics, Inc. Common Stock) Stock Analysis - Politician Trades

Neumora Therapeutics, Inc. Common Stock (NMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, NMRA trades at $1.78 with a market cap of $327.95M and a P/E ratio of -1.18. NMRA moved +3.59% today. Year to date, NMRA is +5.20%; over the trailing twelve months it is +135.71%. Its 52-week range spans $0.61 to $17.19. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces NMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded NMRA stock?

Rallies tracks politician and congressional stock disclosures for NMRA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

NMRA Key Metrics

Key financial metrics for NMRA
MetricValue
Price$1.78
Market Cap$327.95M
P/E Ratio-1.18
EPS$-1.45
Dividend Yield0.00%
52-Week High$17.19
52-Week Low$0.61
Volume10
Avg Volume0
Revenue (TTM)$0
Net Income$-236.93M
Gross Margin0.00%

Latest NMRA News

Recent NMRA Insider Trades

  • Aurora Daljit Singh sold 6.17K (~$21.92K) on Feb 17, 2026.
  • Pinto Joshua sold 5.97K (~$21.09K) on Feb 17, 2026.
  • BERNS PAUL L sold 9.82K (~$34.46K) on Feb 17, 2026.

NMRA Analyst Consensus

7 analysts cover NMRA: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.

Common questions about NMRA

Which politicians traded NMRA stock?
Rallies tracks politician and congressional stock disclosures for NMRA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in NMRA?
Yes. Rallies tracks politician and congressional stock disclosures for NMRA, including reported purchases, sales, dates, owners, and trade amounts when available.
Is NMRA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NMRA. It does not provide personalized investment advice.
NMRA

NMRA